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osting by EAbstract Objective: To assess the trend of using pharmacoeconomic information by Pharmacy
and Therapeutics (P&T) committees when making formulary decisions.
Design: A cross-sectional study conducted in 2007, using structured survey questionnaires which were
distributed to members of the P&T committees in 11 different hospitals in Riyadh, Saudi Arabia.
Results: A total of 100 survey questionnaires were sent to head of pharmacy departments of 11 differ-
ent hospitals in Riyadh, Saudi Arabia. Out of these, 48 questionnaires were completed and returned. Of
the total respondents participated in the study, 64.58% were medical doctors and 16.66% were phar-
macists and 75% of the respondents said they have applied pharmacoeconomic evaluations in their
decision making process. More than 80% of the respondents perceived that they had a fair knowledge
of pharmacoeconomics. Approximately 80% of respondents expressed some degree of agreement that
pharmacoeconomics should be applied as a decision making tool. The majority of decision-makers
(95%) expressed the interest in attending workshops on pharmacoeconomics.
Conclusion: The study showed that pharmacoeconomics can play an important role in the P&T com-
mittee formulary decisions. However, more education to health care professionals and to hospital
administrators should be conducted to facilitate the use of such a tool. Also, hospitals should recruit
health care professionals with pharmacoeconomic expertise to manage limited health resources in
the best way available.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.. Production and hosting by
Saud University.
lsevier1. Introduction
Health care providers are under pressure to control the rapid
acceleration of health care costs. In the United States, expen-
ditures on prescription drugs accounted for 9.4% of total
health care costs in 2000, making medications the most
inﬂuential driver of health care inﬂation (Shah et al., 2003;
CMS, 2010). In Australia, Canada, Finland, Ireland, Sweden
and the United States, spending on medicines has increased
by more than 70% in real terms between 1990 and 2001.
52 M.S. AlsultanMedicines now make up more than 10% of health spending in
nearly all of these countries (OECD, 2003). The United States
spent 16% of its national income (GDP) on health in 2007.
Apart from the United States, even France, Switzerland and
Germany spend the greatest proportion of national income
on health, which allocated 11.0%, 10.8% and 10.4% of their
GDP to health, respectively (OECD, 2009). In Saudi Arabia
and other Arabian Gulf countries, budget allocations for med-
ications and drug products have increased sharply over the re-
cent years, with a greater percentage of health care costs
devoted to medications. The available data revealed that Saudi
Arabia spent an estimated 4% of its GDP on health care pro-
vision in 2007, which is low in comparison with most devel-
oped countries but similar to other Gulf Co-operation
Council states (Saudi Market Proﬁle, 2008). A study con-
ducted in 2001 in Saudi Arabia reveals that the average house-
hold spent a mean of $587.50 on health related matters,
whereas the mean health expenses in other Gulf countries were
$342.50 (P< 0.005). The cost of total drug consumption
by families in Saudi Arabia was calculated to be $779,673,
913.00 (about 3.0 billion Saudi riyals [SR]). Data from the
same study reveal that families in Saudi Arabia spend 16.3%
more than families in other Gulf countries for medication
(Abou-Auda, 2003).
The increase in expenditure of health care has prompted
many governments, health insurance companies, and health
providers throughout the world to adopt strategies to man-
age the high cost of medication, including formulary man-
agement and the use of pharmacoeconomics. Formulary
management uses pharmacoeconomics as a means to reduce
these costs by allowing efﬁcient use of the available re-
sources. Some studies suggested that decrease in drug expen-
ditures and ultimately the overall cost savings can be
achieved by using well-controlled formularies (Hazlet and
Hu, 1992; Baluch et al., 1999; Green et al., 1989). Pharma-
coeconomic data can support the inclusion or exclusion of a
drug on or from the formulary and support practice guide-
lines that promote the most cost-effective use of medica-
tions. The formulary is a regularly revised collection of
pharmaceuticals based on current clinical judgment and
helps the medical staff of a given institution and experts
in the diagnosis and treatment of disease (ASHP, 1995;
AMCP, 1997). Various strategies can be used to incorporate
pharmacoeconomics into formulary decision making. These
include using published pharmacoeconomic studies, eco-
nomic modeling techniques, and conducting local pharmaco-
economic research. The American Society of Health-System
Pharmacists (ASHP) recommends the use of formulary man-
agement in hospital setting to manage the quality and costs
of pharmaceuticals in order to optimize patient care by
ensuring access to clinically appropriate, safe, and cost-effec-
tive medications (ASHP, 2008). The role of Pharmacy and
Therapeutics (P&T) committees is to make sure deliverance
of safe and effective drug therapy (Quinn and Barisano,
1999). A Medline search utilizing the keywords ‘‘pharmaco-
economics and Saudi Arabia’’ revealed that the use of
pharmacoeconomics in formulary decisions has not been
studied before in the country. Therefore, the objective of this
study was to assess the trend of using pharmacoeconomic
information by Pharmacy and Therapeutics committees
when making formulary decisions in different hospitals in
Riyadh, Saudi Arabia.2. Methods
This was a cross-sectional study conducted in 2007. A struc-
tured survey questionnaire was developed and distributed to
members of the P&T committees in 11 different hospitals in
Riyadh, Saudi Arabia. Hospitals including ministry of health
and general organization hospitals, university and academic
hospitals, military hospitals, and private hospitals were se-
lected to represent the different health care settings in Riyadh.
The hospitals having 300 or more total qualiﬁed beds were in-
cluded into the study. The survey questionnaire was developed
using an earlier study (Odedina et al., 2002) and was pre-tested
by ten pharmacists experienced in formulary decisions to check
for face validity and the ease of administering such a survey.
Some questions in the survey were modiﬁed after getting feed-
back from participants in the pilot study. After verifying the
number of members in the P&T committee, a total of 100 sur-
veys questionnaire, with a covering invitation letter to take
part in the study, were sent to head of pharmacy departments
in the participating organization. The questionnaire covered
the following issues: (i) demographic information such as: edu-
cation degree(s), age, years in the profession, years in the P&T
committee, and the structure and number of the P&T commit-
tee members; (ii) rate the inﬂuence of physicians, pharmacists,
and other members in the P&T committee decisions; (iii) rate
the importance of different factors such as: drug efﬁcacy,
safety, acquisition cost, physicians demand, and other factors
when making formulary decisions; (iv) if pharmacoeconomic
evaluation has ever been used when making decisions and if
the answer was yes, participants were asked to: (a) select the
type of pharmacoeconomic studies used, (b) rate the usefulness
of such studies, (c) the source of such studies, (d) rate the inﬂu-
ence of such studies on the P&T committee decisions, (e) rate
his/her knowledge in pharmacoeconomics; (v) if limited or no
studies have been used members were asked to select from a list
of potential reasons; (vi) rate his/her opinion on whether phar-
macoeconomic evaluation should be a requirement when mak-
ing formulary decisions; and ﬁnally (vii) would the member be
interested in attending a workshop about pharmacoeconomics.
2.1. Data analysis
Responses to each question were coded individually, and data
were analyzed using statistical software PASW 18 (SPSS Inc.,
Chicago, IL). Descriptive statistics was used for data analysis.3. Results
A total of 100 survey questionnaires were sent to head of phar-
macy departments of 11 different hospitals in Riyadh, Saudi
Arabia. Out of the 100 questionnaires distributed, 48 question-
naires were completed and returned.
3.1. Demographic information
Of the 48 respondents participated in the study, 31 (64.58%)
were medical doctors and 8 (16.66%) were pharmacists. The
majority of respondents have more than 10–20 years of experi-
ence as health care professionals. Most of the participants
(83%) had served on the P&T committee for less than 5 years.
Members of the P&T committee in these hospitals consisted of
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macists (range, 1–6 members), and a range of 1–3 members
from other health professionals (Table 1). In response to the
question regarding the inﬂuence of different professions on
the P&T committee decisions, most of the respondents
(75%) believed that physicians and pharmacists can manipu-
late equally the decisions of the P&T committee (Table 2).
3.2. Formulary decision-making criteria
The respondents were asked to rate the importance of drug
efﬁcacy, drug safety, acquisition cost and physician demandTable 1 Summary of demographic information.
Variable N= 48 (%)
Age (years) 25–40 22 (29.7)
>40–55 22 (29.7)
>55 3 (6.4)
Educational level BS Pharmacy 5 (10.4)
PharmD 3 (6.3)
MD 25 (52.1)
MS 6 (12.5)
PhD 7 (14.6)
Other 2 (4.2)
Years as health professional <10 9 (18.8)
>10–20 27 (56.3)
>20 12 (25)
Years in P&T committee <5 40 (83.3)
>5–10 4 (8.3)
>10 3 (6.3)
Number (ratio) of diﬀerent professions in P&T committee
Physicians 4–8 physician
Pharmacists 1–6 pharmacist
Others 1–3 other professions
Table 2 Inﬂuence of different professions on the P&T
committee decisions.
Level of inﬂuence Profession
Physicians Pharmacists Others
Not inﬂuential 2 1 9
Somewhat inﬂuential – 1 14
Inﬂuential 9 9 11
Very inﬂuential 19 21 4
Extremely inﬂuential 17 15 1
Table 3 Important criteria in formulary decision-making.
Factors Rating criteria
Not important Somewhat important
Drug eﬃcacy – –
Drug safety
Acquisition cost – 6
Physician demand – 4
Other factors 4 4for formulary decision making. The results are reported in Ta-
ble 3. The top three criteria rated as ‘‘very or extremely impor-
tant’’ for formulary decision-making were safety and efﬁcacy
(97.9%), the acquisition cost (56.25%) and physician demand
(52.08%).
3.3. Use of pharmacoeconomics in formulary decision-making
process
Respondents were asked to indicate whether they had applied
pharmacoeconomic evaluations in the past for decision mak-
ing process. Out of the 48 respondents, 36 (75%) of the respon-
dents said they have done so; and of those respondents, 52.7%
stated that they found pharmacoeconomic data to be inﬂuen-
tial; whereas 50.0% found these data helpful (Table 4).
3.4. Usefulness of types of pharmacoeconomic analysis
in formulary assessments
One of the questions in the questionnaire required the respon-
dents to indicate the type of pharmacoeconomic analysis which
they would ﬁnd useful in decision making. The most popular
analysis type was a cost-effectiveness analysis (22.2%). This
was followed by cost-beneﬁt analysis (11.1%); however
47.2% of the respondents used more than one type of pharma-
coeconomic analysis and 13.8% of the respondents were not
sure about the use of the type of pharmacoeconomic analysis
(Table 4).
3.5. Importance of data sources for formulary decision-making
Respondents were asked to indicate the data sources for
pharmacoeconomic studies in formulary decision-making.
About 50.0% of respondents were using more than one
source of information for pharmacoeconomic studies. Among
individual source, the published literatures in peer-reviewed
journals were ranked the top of the list. In-house expertise
and pharmaceutical company as a source of information were
ranked the last and were not considered ‘‘very important’’
(Table 4).
3.6. Awareness of pharmacoeconomics
The respondents were requested to rate their understanding of
pharmacoeconomic data, on a scale of ‘‘no knowledge’’,
‘‘somewhat knowledgeable’’, ‘‘knowledgeable’’, ‘‘very knowl-
edgeable’’, and ‘‘extremely knowledgeable’’. More than 80%
of the respondents perceived that they had a fair knowledge
of pharmacoeconomics and 8.3% indicated that they do not
have knowledge of pharmacoeconomics’’ (Table 4).Important Very important Extremely important
1 19 28
1 18 29
15 21 6
19 24 1
6 3 4
Table 4 Use of pharmacoeconomics in formulary decision-
making process.
Variable N (%)
Ever use pharmacoeconomic data
Yes 36 (75)
No 12 (25)
Type of study used
Cost eﬀectiveness 8 (22.2)
Cost beneﬁt 4 (11.1)
More than one 17 (47.2)
Not sure 5 (13.8)
Usefulness of studies
Not helpful 1 (2.7)
Somewhat helpful 1 (2.7)
Helpful 18 (50.0)
Very helpful 11 (30.5)
Extremely helpful 3 (8.3)
Source of studies
Published literature 11 (30.5)
Pharmaceutical company 2 (5.5)
In house expertise 2 (5.5)
More than one source 18 (50.0)
Pharmacoeconomic inﬂuence
Not inﬂuential –
Somewhat inﬂuential 8 (22.2)
Inﬂuential 19 (52.7)
Very inﬂuential 8 (22.2)
Extremely inﬂuential 1 (2.7)
Pharmacoeconomic knowledge
No knowledge 3 (8.3)
Somewhat knowledgeable 11 (30.5)
Knowledgeable 19 (52.7)
Very knowledgeable 2 (5.5)
Extremely knowledgeable 1 (2.7)
54 M.S. Alsultan3.7. Barriers to use pharmacoeconomic information
for formulary decision-making and future expectations
The respondents in this study have indicated the reason for the
limited use of pharmacoeconomic data to more than oneTable 5 Barriers to use pharmacoeconomics for formulary
decision-making and future expectation.
Variable N (%)
Reason of no or limited use of pharmacoeconomics
Lack of expertise 8 (22.2)
Lack of resources 6 (16.6)
Not required 2 (5.5)
More than one factor 16 (44.4)
Other factors 4 (11.1)
Should pharmacoeconomics be required like the rest of the world
Disagree 6 (12.5)
Not sure 1 (2.1)
Agree 21 (43.7)
Strongly agree 20 (41.7)
Interested in attending a pharmacoeconomic educational workshop
Yes 46 (95.8)
No 2 (4.2)factor (44.4%) including: lack of expertise (22.2%), lack of re-
sources (16.6%), and that pharmacoeconomic data are not re-
quired (5.5%) in the formulary management process. It has
been expressed to some degree of agreement by almost 80%
of respondents that pharmacoeconomics should be applied
as a decision making tool like in the rest of the world. Almost
all the decision-makers (95%) expressed the interest in attend-
ing workshops on pharmacoeconomics (Table 5).4. Discussion
To our knowledge, this study is the ﬁrst of its kind in the King-
dom of Saudi Arabia that examines the use of pharmacoeco-
nomic data and techniques in formulary decision making.
This study had shown that safety and efﬁcacy were the most
important criteria for formulary decision-making followed by
acquisition cost and physician demand criteria. Traditionally,
the most formulary decisions were made on the basis of rela-
tive clinical efﬁcacy, safety, drug interactions, pharmacokinet-
ics, pharmacology, and drug acquisition costs with little
consideration for the overall health-systems costs (Odedina
et al., 2002). In another study it was also revealed that drug
safety and drug efﬁcacy appeared to have a great inﬂuence
on the P&T committee decision making process (Hans et al.,
2003). In a different study in which the role of pharmacoeco-
nomics in drug beneﬁt decision-making was investigated, a re-
sult similar to our study was observed as product efﬁcacy and
safety were rated highest among the considered data in the
drug beneﬁt decision making process (Motheral et al., 2000).
Two thirds of the respondents in our study stated that they
have applied pharmacoeconomic evaluations in their decision
making process. Out of those who have applied pharmacoeco-
nomics in their decision making, more than half of the respon-
dents stated that they found pharmacoeconomic data to be
inﬂuential and helpful. Cost-effectiveness analysis was the
more preferred type of pharmacoeconomic analysis in use by
the respondents in the study. Cost-beneﬁt analysis was the next
most useful type of analysis. This ﬁnding was similar to earlier
studies which indicated that cost-effectiveness analysis is one
of the fundamental principles of pharmacoeconomics, and also
the most commonly used and conducted type of pharmacoeco-
nomic analysis (Harris, 2001). In our study about 50.0% of
respondents were using more than one source of information
for pharmacoeconomic studies. However, among individual
source, the published literature was ranked the top of the list.
In all studies on the subject of pharmacoeconomics and drug
beneﬁt decision-making, peer-reviewed literature was the pre-
ferred source of data used by decision-makers. Peer-reviewed
literature is rated very highly for its validity and quality (Lyles
et al., 1997). More than 80% of the respondents in our study
assumed that they had a fair knowledge of pharmacoeconom-
ics; however, they have indicated the reason for the limited use
of pharmacoeconomic data to lack of expertise and lack of re-
sources when making formulary decisions. Others studies had
also identiﬁed that the ability of drug beneﬁt decision-makers
to understand and interpret pharmacoeconomic data is inade-
quate, and has resulted in the limited use of these data for
making decisions (Mullins and Wang, 2002; Suh et al.,
2002). Now it is the obligation of time for decision-makers
to truly understand pharmacoeconomics in order to make
appropriate decisions for selecting drugs during formulary
The role of pharmacoeconomics in formulary decision making 55decision making process. Almost 80% of the respondents in
our study have expressed some degree of agreement that phar-
macoeconomics should be applied as a tool in formulary deci-
sion making process like the rest of the world. This is raising
the issue of the need for special guidelines on how to conduct
and use pharmacoeconomics in Saudi Arabia similar to other
countries. Decision-makers worldwide have been looking more
frequently at pharmacoeconomics as a basis for cost-effective
treatment (Bentkover and Corey, 2002; Kozma et al., 1993;
Arenas et al., 2005). The applications of pharmacoeconomics
in many countries are used by decision makers when making
formulary, reimbursing decisions, and/or support pricing deci-
sions about new medications. Countries that have made the
use of such application a requirement and have their own
guidelines for that include Australia, Canada, United King-
dom, New Zealand, Sweden, and many other European coun-
tries (Eddama and Coast, 2008, 2009; Vuornkoski et al., 2008;
Williams and Bryan, 2007; Armstrong et al., 2008; Tordoff
et al., 2006). Pharmacoeconomic guidelines provide guidance
on the appropriate concepts to consider or use when conduct-
ing pharmacoeconomic evaluations (Jacobs et al., 1995). The
successful management of a drug formulary is frequently
dependent on the reliability of the criteria and evidence used
to make decisions regarding the inclusion or exclusion of drugs
from formularies. Almost all the decision-makers in our study
expressed the interest in attending workshops on pharmaco-
economics. This ﬁnding was similar to earlier report in which
decision-makers in the United States also expressed the need
for seminars, symposia and workshops on pharmacoeconom-
ics. It has been suggested that pharmaceutical companies
should assist by collaborating to provide educational
programmes, so that decision-makers would more effectively
use pharmacoeconomic information (Bentkover and Corey,
2002).5. Conclusion
Our study showed that pharmacoeconomics can play an
important role in the P&T committee formulary decisions.
However, more education to health care professionals and
to hospital administrators should be conducted to facilitate
the use of such a tool. Also, hospitals should recruit health
care professionals with pharmacoeconomics expertise to help
and manage limited health resources in the best way
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